Bristol-Myers Squibb Co PEG Ratio

Data as of August 04, 2026

How It's Calculated

What This Means

Bristol-Myers Squibb Co has a negative PEG ratio of -8.67, which typically means the company has negative earnings or a negative growth rate. PEG is not meaningful in this scenario.

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Co (BMY) operates in the Pharmaceuticals sector, specifically in Pharmaceuticals. With a market capitalization of about $133.41B, it ranks as a large-cap stock — a major established company.

Shares recently traded near $65.47, within a 52-week range of $42.52 to $65.66 (-0.3% from the high, +54.0% from the low). Beta of 0.23 indicates relatively lower volatility versus the market.

Trailing profit margin is about 12.3%, signaling a solid profit margin for its industry.

Understanding This Metric

The PEG ratio adjusts the PE multiple for expected earnings growth, helping compare fast-growing and slow-growing names on a more equal footing. For Bristol-Myers Squibb Co, a PEG near 1 is often described as fairly valued relative to growth, though the growth estimate itself can change quickly with guidance revisions.

Sector Comparison

Among Pharmaceuticals names on our S&P 100 coverage, Bristol-Myers Squibb Co's PEG ratio of -8.67 can be compared with peers such as LLY (1.03), JNJ (2.37), MRK (2.73). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Pharmaceuticals stocks.

Key Takeaways

• BMY is grouped in the Pharmaceuticals sector for peer comparisons.
• Recent beta of 0.23 suggests lower-than-market price sensitivity.
• Trailing profit margin of 12.3% provides context for how much earnings support the headline multiple.

Related Tools & Guides

Explore calculators and guides connected to this metric, or view all metrics for BMY.

Other BMY Metrics

Frequently Asked Questions